The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Nemtabrutinib in R/R follicular lymphoma
In this video, Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland, briefly discusses the efficacy and safety of nemtabrutinib in patients with relapsed/refractory (R/R) follicular lymphoma, which has been investigated in cohort G of the Phase II BELLWAVE-003 trial (NCT04728893). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Now, talking about the non-covalent BTK inhibitors, we present a couple of studies with nemtabrutinib. Nemtabrutinib is another non-covalent BTK inhibitor developed slightly slower than pirtobrutinib, but in general very similar. So in the studies, once we presented efficacy in follicular lymphoma, that’s what we anticipated would happen. In follicular lymphoma, we used to have a much better result with PI3K inhibitors, which are eventually abandoned, and for the inhibition of BTK, we need a strong drug, a strong inhibition...
Now, talking about the non-covalent BTK inhibitors, we present a couple of studies with nemtabrutinib. Nemtabrutinib is another non-covalent BTK inhibitor developed slightly slower than pirtobrutinib, but in general very similar. So in the studies, once we presented efficacy in follicular lymphoma, that’s what we anticipated would happen. In follicular lymphoma, we used to have a much better result with PI3K inhibitors, which are eventually abandoned, and for the inhibition of BTK, we need a strong drug, a strong inhibition. And that’s why the first approval was with zanubrutinib and obinutuzumab. Now, both second-generation BTK inhibitors, specifically nemtabrutinib, was tested in this population with reasonable results. Again, the same thing as with Pirtobrutinib, relatively good efficacy and a great tolerance.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
